CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Exvastat is developing Impentri, a new treatment for Acute Respiratory Distress Syndrome (ARDS), which aims to reduce mortality rates associated with the condition. This repurposed drug targets the underlying causes of ARDS and is expected to enter human trials soon.
Acute Respiratory Distress syndrome (ARDS) is a life threatening condition that affects 3 million people world-wide.
With regards to the current coronavirus pandemic, ARDS is the immediate cause of death for patients suffering from this infection. 40% of the patients that suffer from the condition succumb to it and among the ones that survive, most of them face long-term physical and mental illness.
The unreliable, costly, prolonged treatment options currently available are responsible for the h…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
